Metformin Use in Patients with Diabetes and Renal Impairment

Introduction to Metformin Management

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide Level 1B evidence supporting metformin use down to eGFR ≥30 mL/min/1.73 m², representing a consensus between KDIGO, FDA labeling, and American Diabetes Association recommendations 1, 2, 3, 5, 6

For patients with eGFR <30 mL/min/1.73 m², discontinue metformin immediately due to increased risk of lactic acidosis 1, 2, 3
For patients with eGFR 30-44 mL/min/1.73 m², reduce the metformin dose to half the maximum recommended dose (maximum 1000 mg daily) 1, 2, 3, 4
For patients with eGFR 45-59 mL/min/1.73 m², if already on metformin, continue the same dose but consider reduction in certain high-risk conditions 1, 2, 3
For patients with eGFR ≥60 mL/min/1.73 m², continue metformin at full therapeutic doses (up to 2550 mg daily for immediate release, 2000 mg for extended release) 1, 2, 3

Increase monitoring frequency as renal function declines: eGFR ≥60, annually; eGFR 45-59, every 3-6 months; eGFR 30-44, every 3-6 months 1, 2, 3
Monitor vitamin B12 levels in patients on metformin for more than 4 years due to the risk of metformin-induced B12 deficiency 1, 2, 3

When eGFR falls below 30 mL/min/1.73 m², prioritize SGLT2 inhibitors and GLP-1 receptor agonists for their cardiovascular and renal protective effects independent of glucose control 1, 2, 6